Another critical modulator recently identified for mesenchymal GBM is sortilin, which is a member of the Vps10p sorting receptor family found to promote GBM invasion mainly via glycogen synthase kinase 3 beta (GSK-3β)/β-catenin/Twist-induced mesenchymal transition, suggesting that AF38469, a novel inhibitor of sortilin, may be a selective antitumor agent for sortilin-overexpressing mesenchymal GBM [172]. Here, GSK3B is linked to glioblastoma.